Restart Life Closes Over-Subscribed Second Tranche Financing

Executive Summary

• Restart Life Sciences Corp. closed the oversubscribed second tranche of its non‑brokered private placement, raising CDN $630,000 and bringing total proceeds to CDN $1.13 million.
• 6,300,000 units were issued at CDN $0.10 per unit; each unit includes one common share and one transferable warrant.
• Proceeds will be used for health‑food trials, potential acquisitions, and general working capital.

Key Details

• Total gross proceeds: CDN $1,130,000 (CDN $630,000 from the second tranche).
• Units issued in second tranche: 6,300,000 units at CDN $0.10 per unit.
• Unit composition: 1 common share + 1 transferable common share purchase warrant (exercise price CDN $0.10, one‑year term).
• Finder warrants: 132,000 non‑transferable finder warrants issued to eligible finders; each grants the right to purchase one common share at CDN $0.10 for one year.
• Hold period: All securities subject to a four‑month‑plus‑one‑day hold period expiring April 18, 2026.
• Use of proceeds: Health food trials, potential acquisitions, and general working capital.

Notable Quotes

(No direct quotes were provided in the release.)